Keyphrases
Liraglutide
94%
End-stage Renal Disease
89%
Type 2 Diabetic Patients
68%
Investigator-initiated
63%
Copenhagen
63%
Heart Failure Risk
63%
Risk Study
63%
Non-insulin-dependent Diabetes Mellitus (NIDDM)
63%
Heart Failure
47%
Type 2 Diabetes Mellitus (T2DM)
40%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
38%
Urinary Albumin Excretion
37%
Dialysis
36%
Elderly Outpatients
33%
Placebo-controlled
31%
Glycemic Efficacy
31%
Continuous Glucose Monitoring
31%
Diabetic Patients
31%
Renal Replacement Therapy
31%
Diagnostic Utility
31%
Atrial Natriuretic Peptide
31%
Denmark
31%
Group-randomized Trial
31%
High Risk
31%
Gene Polymorphism
31%
Genetic Variation
31%
Atopic Dermatitis
31%
Diabetes Mellitus Patients
31%
Nationwide Survey
31%
Low-dose Heparin
31%
Prospective Randomized Trial
31%
Ocular Surface Disease
31%
Proliferative Vitreoretinopathy
31%
Heart Failure Stages
31%
Randomized Placebo-controlled Trial
31%
Nephropathy
31%
High-risk Population
31%
Confidence Interval
31%
Intervention Studies
31%
Adjusted Odds Ratio
31%
Collagen IV
31%
Dialysis-dependent
26%
Hypoglycemic Events
21%
Diabetes
19%
HindIII
18%
Allele Frequency
18%
Genotype Frequency
18%
Number of Patients
15%
Low Molecular Weight Heparin
15%
Conjunctivitis
14%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Liraglutide
94%
End Stage Renal Disease
89%
Placebo
84%
Insulin Dependent Diabetes Mellitus
63%
Antidiabetic Agent
37%
Kidney Disease
36%
Intervention Study
31%
Diabetes Mellitus
31%
Replacement Therapy
31%
Heparin
31%
Heart Failure
31%
Atrial Natriuretic Factor
31%
Proliferative Retinopathy
31%
Low Molecular Weight Heparin
21%
Diabetic Nephropathy
12%
Sodium Chloride
10%
Subcutaneous Injection
10%
Mixed Model
8%
Glucagon Like Peptide 1 Receptor Agonist
7%
Safety Test
7%
Left Ventricular Systolic Dysfunction
7%
Diabetic Retinopathy
6%
Complementary DNA
6%
Genetic Susceptibility
6%
Genomic DNA
6%
Case-Control Study
6%
Biological Marker
5%
Hypoglycemia
5%
Maximum Tolerated Dose
5%
Symptom
5%
Hemoglobin A1c
5%
